News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Alizyme PLC  (AZM.L) Commencement of Phase 2 Study in the U.S.



5/20/2008 12:51:41 PM

Cambridge UK, 20 May 2008: Alizyme plc (LSE: AZM) (“Alizyme”) announces that Prometheus Laboratories Inc. (“Prometheus”), its partner in North America for COLAL-PRED®, has initiated the clinical development of COLAL-PRED® in the US with a Phase II study for the treatment of ulcerative colitis.

The trial is a multi-centre, randomized, double-blind, placebo-controlled, parallel design, dose ranging study of COLAL PRED® for the treatment of ulcerative colitis in approximately 200 patients. Patients will be randomized to placebo or one of four doses of COLAL PRED® (equivalent to 40, 60, 80, or 120 mg of prednisolone) for a treatment period of 4 weeks.

Alizyme is currently developing COLAL-PRED® for the treatment of ulcerative colitis in Europe. Recruitment into the current EU Phase III registration clinical trial in approximately 800 patients with active moderate-to-severe ulcerative colitis completed in 2007 and headline results are expected to be reported in July 2008. Successful results from this EU Phase III trial would allow a Marketing Authorisation Application (“MAA”) to be submitted for the EU in Q4 2008.

Commenting on today’s announcement, Tim McCarthy, Alizyme’s Chief Executive Officer said:

“We are delighted with the news that Prometheus has initiated recruitment into their Phase II study for COLAL-PRED® in the US, a significant market for this product. The commencement of clinical activity in the US for COLAL-PRED® is a key milestone in the development and commercialisation of this product for the global market.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES